Tag Archive: pubmed


Factor AF2 is an extract from the spleen and liver of sheep embryos and lambs. The product contains biotechnologically produced, chromatographically uniform, molecularly standardized polypeptides, glycopeptides, glycolipids and nucleotides, deproteinized and free of pyrogens’. Factor AF2 is intended mainly for use in ‘supportive antitumour therapy’, as a ‘biological antiemetic and analgesic’. The proposed duration of treatment is usually more than six months. The dosage varies considerably according to the indication. The average daily costs are, therefore, between DM 4.- (prevention of recurrence) and DM 107.- (adjuvant to chemotherapy). Allergic reactions have been reported in ‘rare cases’. Factor AF2 was developed in the forties by Guarnieri in Rome. Since 1984, Factor AF2 is ‘biotechnologically’ produced and as a ‘biological response modifier’ (BRM) in the oncotherapy distributed by Biosyn Arzneimittel GmbH, Stuttgart. Dr. rer. nat. T. Stiefel and Dr. rer. nat. H. Porcher are the representatives of Biosyn Arzneimittel GmbH. In the past, both worked with Vitorgan Arzneimittel GmbH (cytoplasmatic therapy according to Theurer). It is claimed that Factor AF2 contains ‘immunomodulating and immunorestorative biomolecules’ assignable to the BRM group. Terms and investigations from current immunological research are applied to Factor AF2. No preclinical investigations are available which demonstrate any cytostatic effect of Factor AF2. In vivo, no effects were observed on the transplanted meth-A-sarcoma in mice.(ABSTRACT TRUNCATED AT 250 WORDS)

PMID:
2349412
[PubMed – indexed for MEDLINE]
Advertisements

The Australian polidocanol (aethoxysklerol) study. Results at 2 years

Source

Department of Surgery, Nepean Hospital, Sydney, Australia.

Abstract

BACKGROUND:

An ongoing study of the safety and effectiveness of polidocanol by 98 investigators in Australia infecting 16,804 limbs over 2 years.

OBJECTIVE:

To evaluate the complications of polidocanol and compare its effectiveness and complications with sodium tetradecyl sulphate (STD) and hypertonic saline.

METHODS:

A single-arm prospective study of polidocanol complications and its effectiveness as a sclerosant was performed. This was compared with each investigator’s previous experience with other sclerosing agents. Patients had either varicose veins or venule ectasias and/or spider veins (telangiectasia). A total of 16,804 limbs were injected by 98 investigators. Sclerotherapy was performed with 0.5% or 1% polidocanol for telangiectasias or spider veins, and with 3% polidocanol for varicose veins. The effectiveness of the sclerotherapy and any complications were reported during a 2-year period.

RESULTS:

There were very few complications reported with polidocanol. There were no reported deaths or anaphylaxis. The investigators with previous experience of other sclerosants considered that the effectiveness of polidocanol was superior to STD (85%) and hypertonic saline (84%). Ninety percent of investigators considered that polidocanol had less frequent complications than STD, and 80% considered that these were less severe. Seventy-four percent considered that polidocanol had fewer side effects than hypertonic saline, and 74% considered that these were less severe.

CONCLUSIONS:

Polidocanol is an effective sclerosant that has few complications.

PMID:
7728486
[PubMed – indexed for MEDLINE]